Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Shoulder Innovations, Inc.NYSE: SI
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$15.38M, compared with $247K a year earlier. Trailing-twelve-month net change in cash was $5.12M.
Context
- Net change in cash amounted to 43.8% of revenue in FY2025, up 43.5 pp from a year earlier.
- Net change in cash increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$15.38M or moves back toward the trailing-twelve-month quarterly average of $1.28M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 20.75M USD
- Year-over-year change
- +18461.1%
- 2-year CAGR
- +181.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.75M | +18461.1% |
| FY2024 | 2024-12-31 | (113K) | -104.3% |
| FY2023 | 2023-12-31 | 2.61M | — |
Net Change in Cash vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 net change in cash of $5.12M is the 10th largest of the 11 companies compared; the peer median is $7.74M.
- Net change in cash amounts to 9.5% of revenue for SI, versus a peer median of 16.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $44.87M | -202.5% | -14.0% | 38.2% | |
| LTM Mar 2026 | $35.93M | +89.5% | +8.8% | — | |
| LTM Mar 2026 | $28.13M | -286.4% | -36.5% | 8.0% | |
| LTM Mar 2026 | $25.29M | +542.2% | -17.4% | 36.5% | |
| LTM Mar 2026 | $18.61M | -347.9% | -40.1% | — | |
| FY2025 | $17.77M | -172.8% | -25.5% | 16.5% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $11.75M | +1066.8% | +102.1% | — |
| LTM Dec 2025 | $9.85M | +157.7% | — | 75.6% | |
| LTM Mar 2026 | $7.71M | +65.2% | +43.6% | 10.8% | |
| LTM Mar 2026 | $5.12M | — | — | 9.5% | |
| LTM Mar 2026 | $2.28M | -59.1% | +47.7% | 5.1% | |
| Peer median (excluding SI) | $7.74M | +3.1% | -14.0% | 16.5% | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 451K | 754K | 996K |
| Change in Working Capital | (4.77M) | (1.04M) | 0 |
| Accounts Receivables | (2.69M) | (575K) | (3.3M) |
| Inventory | (2.41M) | (4.03M) | (7.64M) |
| Accounts Payables | (737K) | 3.12M | 3.37M |
| Other Working Capital | 1.08M | 446K | 0 |
| Other Non-Cash Items | 2.18M | (437K) | 7.54M |
| Operating Cash Flow | (13.14M) | (14.14M) | (28.61M) |
| Capital Expenditures | (2.75M) | (4.02M) | (7.41M) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (29.25M) | (5.28M) | (119.49M) |
| Sales of Investments | 3.03M | 23.26M | 31.3M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (28.97M) | 13.96M | (95.6M) |
| Debt Repayment | 10M | 0 | 0 |
| Common Stock Issued | 34.88M | 66K | 39.51M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (149K) | 66K | 144.96M |
| Financing Cash Flow | 44.73M | 66K | 144.96M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | 2.61M | (113K) | 20.75M |
| Free Cash Flow | (15.89M) | (18.16M) | (36.02M) |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.